Latest financial market updates and expert analysis
Earnings Roche’s oncology division has encountered a significant strategic obstacle. The pharmaceutical giant’s key drug candidate, giredestrant, failed to meet the primary goal in its pivotal “persevERA” Phase III trial. The...
In the biotechnology investment landscape, a company’s long-term viability is frequently determined by its ability to validate scientific research through...
A pivotal shareholder vote next month will determine the future of Dolly Varden Silver, as the company seeks to combine...
Lynas Rare Earths, recognized as the largest producer of rare earth elements outside of China, has achieved significant clarity on...
In a strategic pivot, Goldmining Inc. is intensifying efforts to advance its portfolio of gold and copper projects across the...
Austria’s OMV has released its 2025 annual results, painting a clear picture of a company in transition. The figures reveal...
Infineon stock experienced a sharp decline, plummeting more than 7% in a single trading session after UBS removed its buy...
The Lithuanian Ministry of Finance, as the majority shareholder of Ignitis Grupe AB, has issued a revised strategic framework for...
ReoStar Energy has embarked on a significant operational realignment, setting an ambitious target of achieving full climate neutrality by the...
The agricultural sector is witnessing a fundamental transformation in how crops are protected, with biological solutions moving from niche to...
Cogent Biosciences recently showcased compelling long-term efficacy data for its lead drug candidate, bezuclastinib, at the 2026 American Academy of...
